In the present study, Hu-Mikβ1, a humanized mAb directed at the shared IL-2/IL-15Rβ subunit (CD122) was evaluated in patients with T-cell large granular lymphocytic (T-LGL) leukemia. Hu-Mikβ1 blocked the trans presentation of IL-15 to T cells expressing IL-2/IL-15Rβ and the common γ-chain (CD132), but did not block IL-15 action in cells that expressed the heterotrimeric IL-15 receptor in cis. There was no significant toxicity associated with Hu-Mikβ1 administration in patients with T-LGL leukemia, but no major clinical responses were observed. One patient who had previously received murine Mikβ1 developed a measurable Ab response to the infused Ab. Nevertheless, the safety profile of this first in-human study of the humanized mAb to IL-2/IL-15Rβ (CD122) supports its evaluation in disorders such as refractory celiac disease, in which IL-15 and its receptor have been proposed to play a critical role in the pathogenesis and maintenance of disease activity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548167 | PMC |
http://dx.doi.org/10.1182/blood-2012-08-450585 | DOI Listing |
Int J Biol Macromol
January 2025
College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, PR China. Electronic address:
As a Group 2B carcinogen, accurate and efficient detection for Fumonisin B1 (FB1) is essential. The emergence of aptamers presents a viable solution to meet this demand. In this study, a truncated aptamer named Apt40 was developed, showcasing remarkable binding affinity to FB1.
View Article and Find Full Text PDFThe eastern equatorial Atlantic hosts a productive marine ecosystem that depends on upward supply of nitrate, the primary limiting nutrient in this region. The annual productivity peak, indicated by elevated surface chlorophyll levels, occurs in the Northern Hemisphere summer, roughly coinciding with strengthened easterly winds. For enhanced productivity in the equatorial Atlantic, nitrate-rich water must rise into the turbulent layer above the Equatorial Undercurrent.
View Article and Find Full Text PDFCase Rep Cardiol
January 2025
Department of Cardiology, Toyohashi Heart Center, Toyohashi, Aichi, Japan.
We present a case of a 60-year-old man with claudication in his right foot; the patient had received stent-graft implantation for the right superficial femoral artery (SFA) 1 year ago. Computed tomography angiography suggested stent occlusion of the right SFA, and a thrombus was considered to cause occlusion. To avoid distal embolization, we performed lesion recanalization via a trans-ankle intervention.
View Article and Find Full Text PDFDalton Trans
January 2025
Czech Academy of Sciences, J. Heyrovsky Institute of Physical Chemistry, Dolejškova 2155/3, 182 23 Prague 8, Czech Republic.
Copper isotopes and their complexes are intensively studied due to their high potential for applications in radiodiagnosis and radiotherapy. Here, we study the Cu complex of 1,8-bis(2-hydroxybenzyl)-cyclam (HL), which forms an unexpected variety of isomers differing in the mutual orientation of the substituents on the cyclam nitrogen atoms, the protonation of the phenolate pendant, and the ligand denticity. The interconversion of the isomers is rather slow, which made the isolation, identification and investigation of some of the individual species possible.
View Article and Find Full Text PDFAIDS Behav
January 2025
Center for Drug Use and HIV Research, School of Global Public Health, New York University, New York, NY, USA.
Transgender and gender-expansive young people, ages 13-24 years, experience disproportionate HIV risk yet are among those with the lowest US PrEP uptake rates (< 10%). Factors influencing PrEP outcomes for this population are poorly understood. This study examines the effects of gender minority stressors, gender affirmation, and heavy substance use on their PrEP outcomes using data from the CDC's 2018 START study (N = 972).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!